# Lunit Expands AI-Powered Breast Cancer Screening Across the Stockholm Region

- Link: https://www.thailand-business-news.com/pr-news/lunit-expands-ai-powered-breast-cancer-screening-across-the-stockholm-region
- Published: 2026-09-28T20:00:00+07:00
- Author: PR Newswire

|   |

**Following years of clinical validation and proven real-world performance at Saint
Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent second reader
at regional scale**

SEOUL, South Korea, Sept. 28, 2026 /PRNewswire/ — Lunit (KRX:328130), a leading 
provider of AI for cancer diagnostics and precision oncology, today announced that
its AI-powered mammography solution, Lunit INSIGHT MMG, will be implemented as an
independent second reader across the entire Stockholm Region in Sweden, building
on years of successful clinical validation and real-world use at Capio Saint Göran
Hospital.

The deployment, carried out in collaboration with Sectra, will span three institutions:
Capio Saint Göran Hospital, Karolinska University Hospital, and Södersjukhuset (
Sös). Once fully implemented, the deployment is expected to support between 200,000
and 250,000 examinations annually.

The Stockholm deployment follows Lunit’s earlier regional deployment in Dalarna,
marking the company’s second region-level deployment in Sweden. It builds on several
years of clinical and operational experience at Saint Göran, where the solution 
progressed from prospective clinical evaluation to routine breast cancer screening.
Since its adoption in 2023, Lunit’s AI solution has supported approximately 200,000
examinations over the past three years and has continued to support the screening
workflow through changes in mammography systems, demonstrating its ability to operate
at scale in a real-world screening environment.

That track record began with ScreenTrustCAD, a prospective population-based study
at Saint Göran that evaluated the solution in the real-world screening of more than
55,000 women. One-year real-world results presented at the Radiological Society 
of North America (RSNA) 2024 Annual Meeting later showed a 15% increase in cancer
detection and more than a 36% reduction in radiologists’ reading time, with strong
Normal Flagging performance contributing to improved reading efficiency.

"Building on this progression from clinical research to routine implementation and
real-world validation, the expansion across Stockholm Region represents an important
next step," said Karin Dembrower of Capio Saint Göran Hospital. "It brings an approach
first evaluated and implemented at a single hospital to a broader regional breast
cancer screening environment."

"Stockholm is a powerful example of how rigorous clinical evidence can translate
into real-world adoption and ultimately broader healthcare implementation," said
Brandon Suh, CEO of Lunit. "What began as a prospective clinical study has grown
into routine clinical use and is now expanding to a regional scale. We believe this
evidence-to-adoption journey demonstrates the role clinically validated AI can play
in building more effective and sustainable cancer screening programs worldwide."

The Stockholm Region deployment marks another important milestone in Lunit’s expansion
across Europe, demonstrating how clinical evidence, real-world validation, and routine
implementation can translate into large-scale adoption of AI in population-based
breast cancer screening.

**About** **Lunit**   
Founded in 2013, Lunit (KRX: 328130) is a global leader on
a mission to conquer cancer through AI. Our clinically validated solutions span 
medical imaging, breast health, and biomarker analysis—empowering earlier detection,
smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning from risk prediction and early detection
to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health
solutions support cancer screening in thousands of medical institutions worldwide,
while the Lunit SCOPE platform is used in research partnership with global pharma
and laboratory leaders for biomarker research, and companion diagnostic development.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical
expertise with continuously evolving datasets to deliver measurable impact—for patients,
clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit
is driving the worldwide fight against cancer. Learn more at [lunit.io](http://lunit.io/).

**About Sectra**
Sectra’s enterprise imaging solution provides a unified strategy
for all imaging needs while lowering operational costs. The scalable and modular
solution, with a VNA at its core, allows healthcare providers to grow from ology
to ology and from enterprise to enterprise. Visit Sectra’s website to read more 
about Sectra and why it’s top-ranked in ["Best in KLAS"](https://medical.sectra.com/about-sectra/sectra-pacs-best-in-klas/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Lunit Expands AI-Powered Breast Cancer Screening Across the Stockholm Region ](http://www.prnasia.com/story/archive/5057816_CN57816_0?rand=184833)
